gilead sciences inc (GILD:NASDAQ GS)
As of 8:10 PM 05/17/13 All times are local (Market data is delayed by at least 15 minutes).
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
Gilead%20Sciences%20Inc.%20%28NasdaqGS%3AGILD%29%20signed%20a%20definitive%20agreement%20to%20acquire%20YM%20BioSciences%20Inc.%20%28TSX%3AYM%29%20from%20New%20Enterprise%20Associates%2C%20HealthCor%20Management%20L.P.%2C%20Discovery%20Capital%20Management%2C%20LLC%20and%20others%20for%20approximately%20%24460%20million%20in%20cash%20on%20December%2012%2C%202012.%20Under%20the%20terms%20of%20the%20agreement%2C%20upon%20closing%20of%20the%20proposed%20transaction%2C%20shareholders%20of%20YM%20will%20receive%20%242.95%20per%20common%20share%20in%20cash%2C%20and%20holders%20of%20warrants%20and%20stock%20options%20will%20receive%20a%20cash%20payment%20equal%20to%20the%20difference%20between%20%242.95%20and%20the%20exercise%20price%20of%20such%20warrant%20or%20stock%20option.%20Gilead%20plans%20to%20fund%20the%20acquisition%20with%20cash%20on%20hand.%20Post%20acquisition%20YM%20BioSciences%20will%20operate%20as%20a%20wholly%20owned%20subsidiary%20of%20Gilead.%20Upon%20termination%2C%20YM%20BioSciences%20will%20be%20required%20to%20pay%20a%20termination%20fee%20of%20%2417.5%20million.%0D%0A%0D%0AThe%20closing%20of%20the%20transaction%20is%20subject%20to%20the%20satisfaction%20of%20certain%20other%20customary%20conditions%2C%20including%20court%20approval%20of%20the%20transaction%2C%20applicable%20government%20and%20regulatory%20approvals%2C%20including%20expiration%20or%20termination%20of%20the%20waiting%20period%20under%20the%20United%20States%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%2C%20and%20the%20review%20period%20under%20the%20Competition%20Act%20%28Canada%29%2C%20dissent%20rights%20shall%20not%20exceed%205%25%20of%20the%20aggregate%20number%20of%20common%20shares%20and%20approval%20of%20YM%20shareholders.%20The%20approval%20of%20Gilead%20shareholders%20is%20not%20required%20in%20connection%20with%20the%20proposed%20transaction.%20The%20arrangement%20agreement%20contains%20customary%20non-solicitation%20provisions%2C%20but%20permits%20YM%2C%20in%20certain%20circumstances%2C%20to%20terminate%20the%20arrangement%20and%20accept%20an%20unsolicited%20superior%20proposal%2C%20subject%20to%20fulfilling%20certain%20conditions.%20The%20transaction%20has%20received%20the%20unanimous%20approval%20of%20YM%u2019s%20Board%20of%20Directors.%20Special%20meeting%20of%20YM%20shareholders%20will%20be%20held%20on%20January%2031%2C%202013%20in%20order%20to%20approve%20the%20plan.The%20transaction%20is%20expected%20to%20close%20in%20the%20first%20quarter%20of%202013.%20As%20reported%20on%20January%2018%2C%202013%2C%20Institutional%20Investor%20Services%20and%20Glass%2C%20Lewis%20%26%20Co.%20recommended%20shareholders%20of%20YM%20BioSciences%20Inc.%20to%20vote%20in%20favor%20of%20the%20transaction.%20The%20initial%20waiting%20period%20under%20the%20United%20States%2C%20Hart%20Scott%20Rodino%20Antitrust%20Improvements%20Act%20of%201976%20has%20expired%20without%20any%20action%20by%20the%20Federal%20Trade%20Commission%20or%20the%20Antitrust%20Division%20of%20the%20United%20States%20Department%20of%20Justice.%0D%0A%0D%0AAs%20of%20January%2031%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20shareholders%20of%20YM%20BioSciences.%20The%20transaction%20will%20be%20completed%20on%20or%20about%20February%208%2C%202013.%20On%20February%205%2C%202013%2C%20the%20transaction%20was%20approved%20by%20the%20Supreme%20Court%20of%20Nova%20Scotia.%20The%20transaction%20is%20now%20expected%20to%20be%20complete%20by%20February%208%2C%202013%20and%20the%20common%20shares%20of%20YM%20BioSciences%20will%20be%20delisted%20from%20the%20Toronto%20Stock%20Exchange.%0D%0A%0D%0ABrad%20Wolff%2C%20Ivan%20Farman%20and%20Robert%20Glassman%20of%20Merrill%20Lynch%20Canada%20acted%20as%20fairness%20opinion%20and%20financial%20advisor%20to%20YM%20BioSciences.%20Bloom%20Burton%20%26%20Co.%20acted%20as%20financial%20advisor%20and%20Vanessa%20Grant%2C%20Kathleen%20Keller-Hobson%2C%20Faran%20Umar-Khitab%2C%20Neeta%20Sahadev%2C%20Gloria%20Geddes%2C%20Ash%20Gupta%2C%20Laura%20Monteith%2C%20Ian%20Macdonald%2C%20Mark%20Nicholson%2C%20Mark%20Paciocco%2C%20Anita%20Nador%2C%20Wendy%20Wagner%2C%20Kristine%20Robidoux%2C%20Sean%20Murphy%2C%20Tal%20Cyngiser%20and%20Matthew%20Literovich%20of%20Gowling%20Lafleur%20Henderson%20LLP%2C%20Sonia%20Yung%20of%20Heenan%20Blaikie%20LLP%20and%20Daniel%20M.%20Miller%20and%20Jeffrey%20Peterson%20of%20Dorsey%20%26%20Whitney%20LLP%20acted%20as%20legal%20advisors%20to%20YM%20BioSciences.%20Ian%20Edvalson%2C%20Martin%20W.%20Korman%20and%20Denny%20Kwon%20of%20Wilson%20Sonsini%20Goodrich%20%26%20Rosati%2C%20Professional%20Corporation%20and%20Michael%20Gans%20of%20Blake%20Cassels%20and%20Graydon%20LLP%20acted%20as%20legal%20advisors%20to%20Gilead.%20CIBC%20Mellon%20Trust%20Company%20acted%20as%20depository%20to%20YM%20BioSciences.%20Philip%20Richter%20of%20Fried%2C%20Frank%2C%20Harris%2C%20Shriver%20%26%20Jacobson%20LLP%20acted%20as%20legal%20advisor%20for%20Merrill%20Lynch%20Canada.
To
mm/dd/yyyy
mm/dd/yyyy
From
mm/dd/yyyy
mm/dd/yyyyDate Range for Stats (05/19/2013 to 05/19/2013)
|
-- High-- Low## % Change |
0 Number of Dividends Paid-- Average Dividend Paid$0.00 Dividends Paid Per Period |
0 Splits25 Transactions365 Days In Range |
Select View:
Open, High, Low, and Close are split adjusted. Adjusted close reflects dividend payouts.
Stock Quotes
Market data is delayed at least 15 minutes.
| Recently Viewed | |||
| GILD:US | $56.30 USD | +1.34 |  |
COMPETITOR HISTORICAL STOCK QUOTES
| Company | % Change | ||
| AbbVie Inc | -- | $47.17 USD | -- |
| Amgen Inc | -- | $105.63 USD | -- |
| Astellas Pharma ... | -- | ¥5,830 JPY | -- |
| Bristol-Myers Sq... | -- | $43.30 USD | -- |
| Eli Lilly & Co | -- | $55.90 USD | -- |
| View Industry Companies | |||
Day VS. Day Stock Price Comparison
| Open | ||
| High | ||
| Low | ||
| Close | ||
| Volume |
Post a JobJobs
- San Dimas, CA | Gilead SciencesPosted: May 18
- Foster City, CA | Gilead SciencesPosted: May 18
- Foster City, CA | Gilead SciencesPosted: May 18
- San Dimas, CA | Gilead SciencesPosted: May 18
Sponsored Financial Commentaries
Sponsored Links
Report Data Issue
To contact GILEAD SCIENCES INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.
Please enter your information in the following field(s):
Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
